IL122427A0 - Pharmaceutical compositions and methods for inhibition of adaptor protein/tyrosine kinase interactions - Google Patents

Pharmaceutical compositions and methods for inhibition of adaptor protein/tyrosine kinase interactions

Info

Publication number
IL122427A0
IL122427A0 IL12242796A IL12242796A IL122427A0 IL 122427 A0 IL122427 A0 IL 122427A0 IL 12242796 A IL12242796 A IL 12242796A IL 12242796 A IL12242796 A IL 12242796A IL 122427 A0 IL122427 A0 IL 122427A0
Authority
IL
Israel
Prior art keywords
inhibition
methods
pharmaceutical compositions
tyrosine kinase
adaptor protein
Prior art date
Application number
IL12242796A
Other languages
English (en)
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Publication of IL122427A0 publication Critical patent/IL122427A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)
IL12242796A 1995-06-07 1996-06-05 Pharmaceutical compositions and methods for inhibition of adaptor protein/tyrosine kinase interactions IL122427A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47613695A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
IL122427A0 true IL122427A0 (en) 1998-06-15

Family

ID=23890650

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12242796A IL122427A0 (en) 1995-06-07 1996-06-05 Pharmaceutical compositions and methods for inhibition of adaptor protein/tyrosine kinase interactions

Country Status (11)

Country Link
US (4) US5780496A (2)
EP (1) EP0831809A4 (2)
JP (1) JPH11506770A (2)
KR (1) KR19990022369A (2)
CN (1) CN1192680A (2)
AR (1) AR003140A1 (2)
BR (1) BR9609353A (2)
CA (1) CA2224103A1 (2)
IL (1) IL122427A0 (2)
MX (1) MX9709442A (2)
WO (1) WO1996040115A1 (2)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04278450A (ja) 1991-03-04 1992-10-05 Adam Heller バイオセンサー及び分析物を分析する方法
US5593852A (en) * 1993-12-02 1997-01-14 Heller; Adam Subcutaneous glucose electrode
US6376529B1 (en) 1995-06-07 2002-04-23 Peng Cho Tang Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
US5786488A (en) * 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
CA2274145A1 (en) * 1996-12-03 1998-06-11 Sugen, Inc. Adaptor protein frs2 and related products and methods
US6051597A (en) * 1997-06-13 2000-04-18 Merck & Co., Inc. Indolylquinones as antidiabetic agents
WO1999043636A2 (en) 1998-02-27 1999-09-02 The United States Of America As Represented By Thesecretary Of The Department Of Health And Human Services Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
US6077849A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antidiabetic agents
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) * 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US20080076997A1 (en) * 1998-04-30 2008-03-27 Abbott Diabetes Care, Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
WO2000056760A1 (en) * 1999-03-23 2000-09-28 The United States Of America, Represented By Secretary, Department Of Health And Human Services Phenylalanine derivatives
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
AU780697B2 (en) 1999-10-22 2005-04-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Inhibition of cell motility and angiogenesis by inhibitors of the GRB2 SH2-domain
US6165728A (en) * 1999-11-19 2000-12-26 Isis Pharmaceuticals Inc. Antisense modulation of NCK-2 expression
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
WO2002016407A2 (en) * 2000-08-22 2002-02-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sh2 domain binding inhibitors
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7151162B2 (en) * 2001-12-06 2006-12-19 The University Of Children's Hospital Of Both Cantons Of Basel Nuclear protein
US7057052B2 (en) * 2002-09-26 2006-06-06 Duke University Heterocyclic quinones as pharmaceutical agents
AU2003303597A1 (en) 2002-12-31 2004-07-29 Therasense, Inc. Continuous glucose monitoring system and methods of use
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
US8600920B2 (en) * 2003-11-28 2013-12-03 World Assets Consulting Ag, Llc Affinity propagation in adaptive network-based systems
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
EA012613B1 (ru) * 2004-12-06 2009-10-30 Авентис Фарма С.А. Замещённые индолы, содержащие их композиции, способ получения и применение
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
NZ601635A (en) * 2010-01-27 2013-06-28 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
US9912758B2 (en) 2014-12-16 2018-03-06 Yahoo Holdings, Inc. Continuing an application session on a different device
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917820A (en) * 1969-05-29 1975-11-04 Canadian Patents Dev Antibiotic cochliodinol and production by chaetomium, cochliodes and chaetomium globsum
JPH0236591B2 (ja) * 1979-08-27 1990-08-17 Kyoto Pharma Ind Kinonjudotai
JPS6191167A (ja) * 1984-10-08 1986-05-09 Kyoto Yakuhin Kogyo Kk キノン誘導体
JPS6360966A (ja) * 1986-08-29 1988-03-17 Kyoto Yakuhin Kogyo Kk キノン誘導体
SE8903455D0 (sv) * 1989-10-19 1989-10-19 Joakim Nelson Dynamiska digitala foerbindelsenaet (dfn)
US5469431A (en) * 1993-07-12 1995-11-21 Philips Electronics North America Corp. Method of and apparatus for channel mapping with relative service identification
DE4329010A1 (de) * 1993-08-28 1995-03-02 Sel Alcatel Ag Funksystem
US6205143B1 (en) * 1996-03-14 2001-03-20 Telefonaktiebolaget L M Ericsson System supporting variable bandwidth asynchronous transfer mode network access for wireline and wireless communications
US5841777A (en) * 1996-08-30 1998-11-24 Hewlett-Packard Company System and method for accommodating ABR and CBR traffic on a shared communications channel
US6363058B1 (en) * 1997-09-24 2002-03-26 Telefonaktiebolaget L M Ericsson (Publ) Multi-service handling by a single mobile station
FI980293L (fi) * 1998-02-09 1999-08-10 Nokia Networks Oy Multimedia- ja monipalvelupuhelut matkaviestinverkossa
WO2000033589A1 (en) * 1998-11-30 2000-06-08 Nokia Networks Oy Air interface capacity scheduling method

Also Published As

Publication number Publication date
MX9709442A (es) 1998-02-28
AU5979996A (en) 1996-12-30
WO1996040115A1 (en) 1996-12-19
CA2224103A1 (en) 1996-12-19
KR19990022369A (ko) 1999-03-25
US6090838A (en) 2000-07-18
AU697120B2 (en) 1998-09-24
CN1192680A (zh) 1998-09-09
BR9609353A (pt) 1999-05-11
EP0831809A4 (en) 2001-11-28
EP0831809A1 (en) 1998-04-01
US6239161B1 (en) 2001-05-29
AR003140A1 (es) 1998-07-08
US5780496A (en) 1998-07-14
US20020016353A1 (en) 2002-02-07
JPH11506770A (ja) 1999-06-15

Similar Documents

Publication Publication Date Title
EP0831809A4 (en) METHODS AND COMPOUNDS FOR INHIBITING ADAPTIVE PROTEIN / TYROSINE KINASE INTERACTIONS
PL330814A1 (en) Compounds for and methods of delivering pharmaceutical preparations and their application
HUP0004490A3 (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threoning kinase inhibitors and pharmaceutical compositions containing them
PL328868A1 (en) Inhibitors of pharnesil protein transferase
AU4915796A (en) Inhibitors of prenyl transferases
NZ305254A (en) Farnesyl protein inhibitors and pharmaceutical compositions thereof
AU2747497A (en) Compositions and methods for antisense inhibition of protein translation
HUP0103520A3 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
IL161833A0 (en) Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases
HUP9901780A3 (en) Imid derivatives as phosphodiesterases and tnf inhibitors and pharmaceutical compositions containing them
AP2001002270A0 (en) Metalloproteinaise inhibitors pharmaceutical compositions containing them and their pharmaceeutical uses and methods and intermediates useful for their preparation
AU5324996A (en) Protein kinase c inhibitors
IL133470A0 (en) Inhibitors of farnesyl protein transferase and pharmaceutical compositions containing same
AU7371998A (en) Inhibitors of protein isoprenyl transferases
AU2096895A (en) Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
IL120141A (en) Substituted quinazoline derivatives process for their preparation and pharmaceutical compositions containing them
AU8681798A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
AU2710597A (en) Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
AU8681698A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
PL323904A1 (en) C-4' modified inhibitors of andenosinic kinase
HUP9902105A3 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein